181 related articles for article (PubMed ID: 21983248)
1. Intravitreal tissue plasminogen activator to treat refractory diabetic macular edema by induction of posterior vitreous detachment.
Abrishami M; Moosavi MN; Shoeibi N; Hosseinpoor SS
Retina; 2011 Nov; 31(10):2065-70. PubMed ID: 21983248
[TBL] [Abstract][Full Text] [Related]
2. Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema.
Sivaprasad S; Ockrim Z; Massaoutis P; Ikeji F; Hykin PG; Gregor ZJ
Retina; 2008; 28(10):1435-42. PubMed ID: 18628722
[TBL] [Abstract][Full Text] [Related]
3. Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion.
Murakami T; Takagi H; Ohashi H; Kita M; Nishiwaki H; Miyamoto K; Watanabe D; Sakamoto A; Yamaike N; Yoshimura N
Retina; 2007 Oct; 27(8):1031-7. PubMed ID: 18040240
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.
Cardillo JA; Melo LA; Costa RA; Skaf M; Belfort R; Souza-Filho AA; Farah ME; Kuppermann BD
Ophthalmology; 2005 Sep; 112(9):1557-63. PubMed ID: 16019075
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema.
Mirshahi A; Shenazandi H; Lashay A; Faghihi H; Alimahmoudi A; Dianat S
Retina; 2010 Feb; 30(2):254-9. PubMed ID: 20057344
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial.
Bonini-Filho MA; Jorge R; Barbosa JC; Calucci D; Cardillo JA; Costa RA
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3845-9. PubMed ID: 16186372
[TBL] [Abstract][Full Text] [Related]
7. [Triamcinolone in the treatment of the diabetic macular edema--one-year results].
Dusová J; Studnicka J; Rencová E; Korda V; Hejcmanová D
Cesk Slov Oftalmol; 2008 Jul; 64(4):149-52. PubMed ID: 18780654
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal tissue plasminogen activator to treat macular edema associated with branch retinal vein occlusion.
Murakami T; Takagi H; Kita M; Nishiwaki H; Miyamoto K; Ohashi H; Watanabe D; Yoshimura N
Am J Ophthalmol; 2006 Aug; 142(2):318-20. PubMed ID: 16876516
[TBL] [Abstract][Full Text] [Related]
9. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema.
Ozdek S; Bahçeci UA; Gürelik G; Hasanreisoğlu B
J Diabetes Complications; 2006; 20(4):246-51. PubMed ID: 16798476
[TBL] [Abstract][Full Text] [Related]
10. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema.
Jonas JB; Spandau UH; Kamppeter BA; Vossmerbaeumer U; Harder B; Sauder G
Ophthalmology; 2006 May; 113(5):800-4. PubMed ID: 16530840
[TBL] [Abstract][Full Text] [Related]
11. Predictability of vitreous detachment following intravitreal plasmin injection in diabetic macular edema associated with vitreomacular traction.
Elbendary AM; Elwan MM; Azzam HA; Eldeeb DR
Curr Eye Res; 2011 Jun; 36(6):534-9. PubMed ID: 21591862
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg.
Audren F; Lecleire-Collet A; Erginay A; Haouchine B; Benosman R; Bergmann JF; Gaudric A; Massin P
Am J Ophthalmol; 2006 Nov; 142(5):794-99. PubMed ID: 16978576
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial.
Massin P; Audren F; Haouchine B; Erginay A; Bergmann JF; Benosman R; Caulin C; Gaudric A
Ophthalmology; 2004 Feb; 111(2):218-24; discussion 224-5. PubMed ID: 15019365
[TBL] [Abstract][Full Text] [Related]
14. Intrasurgical plasmin enzyme in diabetic macular edema.
Azzolini C; D'Angelo A; Maestranzi G; Codenotti M; Della Valle P; Prati M; Brancato R
Am J Ophthalmol; 2004 Oct; 138(4):560-6. PubMed ID: 15488781
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial.
Gillies MC; Sutter FK; Simpson JM; Larsson J; Ali H; Zhu M
Ophthalmology; 2006 Sep; 113(9):1533-8. PubMed ID: 16828501
[TBL] [Abstract][Full Text] [Related]
16. Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema.
Ozdemir H; Karacorlu M; Karacorlu SA
Am J Ophthalmol; 2005 Aug; 140(2):251-5. PubMed ID: 15992756
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial.
Audren F; Erginay A; Haouchine B; Benosman R; Conrath J; Bergmann JF; Gaudric A; Massin P
Acta Ophthalmol Scand; 2006 Oct; 84(5):624-30. PubMed ID: 16965492
[TBL] [Abstract][Full Text] [Related]
18. Optical coherence tomographic pattern may predict visual outcome after intravitreal triamcinolone for diabetic macular edema.
Gibran SK; Khan K; Jungkim S; Cleary PE
Ophthalmology; 2007 May; 114(5):890-4. PubMed ID: 17467527
[TBL] [Abstract][Full Text] [Related]
19. Adverse events after intravitreal infliximab (Remicade).
Giganti M; Beer PM; Lemanski N; Hartman C; Schartman J; Falk N
Retina; 2010 Jan; 30(1):71-80. PubMed ID: 19996827
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal dexamethasone for diabetic macular edema: a pilot study.
Chan CK; Mohamed S; Lee VY; Lai TY; Shanmugam MP; Lam DS
Ophthalmic Surg Lasers Imaging; 2010; 41(1):26-30. PubMed ID: 20128566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
